Recent Updates
Recently added Catalysts

Solid Biosciences Inc.

SLDBFDA catalysts, PDUFA dates & pipeline intelligence
$6.23
▼ -0.25 · -3.86%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SLDB financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $4.2452W HIGH $11.45
Volume
1.13 M
Value Traded
7.11 M
Short % Float
14.61%
Days to Cover
10.7
-18.03%Week
+5.24%1 Month
-36.04%3 Month
-3.71%6 Month
-88.65%5 Year
-98.27%All Time

Cash Data

Unlock SLDB cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
695.33 M
EPS (TTM)
-1.93
P/E Ratio
-
Ent. Value
346.41 M
Total Shares
111.61 M
Float Shares
91.06 M
Insiders
18.41%
Institutions
90.28%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
IND Submission
SGT-601
TNNT2 Thin Filament Cardiomyopathy
Pre-clinicalGene TherapiesCardiovascular
Unlock every SLDB catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SLDB Catalyst Timeline

Dated clinical, regulatory and corporate events for Solid Biosciences Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Solid Biosciences Inc.

241Total events
7Upcoming
43Tier-1 (high impact)
2017 to 2028Coverage

Upcoming catalysts 2

T1FDA Approval
Subscribe to view catalyst details
SGT-003
T1Topline Readout
Subscribe to view catalyst details
SGT-212

Event history 50

●Trial InitiationSGT-501Trial
Sites activated and participant screening commenced in Phase 1b ARTEMIS trial
catecholaminergic polymorphic ventricular tachycardiasource ↗
●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Safety Data UpdateSGT-003Clinical Data
SGT-003 generally well tolerated in 53 participants dosed in INSPIRE DUCHENNE
Duchenne muscular dystrophysource ↗
▲Safety Data UpdateSGT-212Clinical Data
Five participants dosed with SGT-212, no treatment-related SAEs
Friedreich's ataxiasource ↗
▲EU Orphan DesignationSGT-212Ex-US Regulatory
EC grants Orphan designation to SGT-212 for Friedreich's ataxia
Friedreich's ataxiasource ↗
▲Enrollment UpdateSGT-212Trial
Five participants dosed in Phase 1b FALCON trial of SGT-212
Friedreich's ataxiasource ↗
▲EU Orphan DesignationSGT-212Ex-US Regulatory
SGT-212 received Orphan designation from European Commission for Friedreich's ataxia
Friedreich's ataxiasource ↗
●Trial InitiationSGT-501Trial
Clinical trial sites activated and participant screening commenced for ARTEMIS
Catecholaminergic polymorphic ventricular tachycardia (CPVT)source ↗
●Quarterly UpdateCorporate
Q2 2026 financial results reported
●ATM ProgramCorporate
Additional $15.7 million net proceeds from ATM sales after June 30, 2026
Unlock the full SLDB catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SLDB actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-28SGT-003 Phase 1/2 data presentation Phase 1/2
Unlock 7 more SLDB historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 27%
Micro Cap
(rank 196 of 725)
Percentile Rank
Showing 4 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SGT-003 Gene TherapiesNCT06138639Duchenne Muscular DystrophyPhase 3 RECRUITING 140May 6, 2031
SGT-501 Gene TherapiesNCT07148089Catecholaminergic Polymorphic Ventricular TachycardiaPhase 1 RECRUITING 18May 1, 2031
SGT-212 Gene TherapiesNCT07180355Friedreich's Ataxia (FA)Phase 1 RECRUITING 10Feb 29, 2032
SGT-001 Gene TherapiesNCT03368742Duchenne Muscular DystrophyPhase 1/2 ACTIVE NOT_RECRUITING 12Nov 30, 2026
Unlock the SLDB pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SLDB program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
SGT-003
Fast TrackRare Pediatric
Duchenne muscular dystrophyPhase 1/22026-01-14Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimenRead MoreSolid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101Read More
Scroll for more · summaries link to the source press release
Unlock every SLDB trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SLDB insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Brooks GabrielOfficer (Chief Medical Officer)Sell -4,374 97,241 held$5.62 10/19/2026
Unlock the full SLDB insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RA CAPITAL MANAGEMENT, L.P. 0.9 % (-10 %) 87.02 M 12.04 M
Unlock every fund holding SLDB
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SLDB
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SLDB ownership
Insider and institutional ownership, quarter by quarter.

SLDB Short Interest

Shares sold short, counted twice a month.

14.61%
Short % of Float
of tradable shares sold short
13.3M
Shares Sold Short
+8.2% vs prior count
10.7 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Unlock SLDB short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock SLDB option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SLDB option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SLDB options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SLDB ranks across every disease it competes in

Competitive Position is a premium feature
See how SLDB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SLDB News

SLDB
Nov 10, 2026
SLDBConferences/Events

Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Solid Biosciences Inc. will participate in the 2026 Jefferies Global Healthcare Conference. CEO Bo Cumbo is scheduled for a fireside chat on November 16, 2026. The company focuses on developing gene therapies for rare neuromuscular and cardiac diseases. They aim to enhance patient care and advance their diverse pipeline.

Read more →
SLDB
Nov 5, 2026
SLDBConferences/Events
▼ -5.2%on this newsshared move

Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

Solid Biosciences Inc. will engage in one-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026. The company is dedicated to developing precision genetic medicines for neuromuscular and cardiac diseases. Their pipeline includes therapies for conditions like Duchenne muscular dystrophy and Friedreich’s ataxia.

Read more →
SLDB
Nov 4, 2026
SLDBGeneral
▼ -5.2%on this newsshared move

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported its Q3 2026 financial results, highlighting progress in its Duchenne and Friedreich's ataxia programs. The company plans to meet with the FDA to discuss SGT-003's accelerated approval pathway. Additionally, SGT-212 has been well tolerated in its Phase 1b trial, with initial data expected in Q1 2027.

Read more →
SLDB
Oct 26, 2026
SLDBPhases

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia

Solid Biosciences announced that the European Commission granted Orphan designation to SGT-212 for Friedreich's ataxia. The company reported that five participants have been dosed in the Phase 1b FALCON trial, which has shown no serious adverse events. Initial clinical data from the trial is anticipated in the first quarter of 2027.

Read more →
SLDB
Oct 20, 2026
SLDBConferences/Events
▲ +8.1%on this news

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

Solid Biosciences Inc. announced that seven abstracts will be presented at the ESGCT 2026 Annual Congress in Hamburg, Germany. The research focuses on gene therapy advancements, particularly for Duchenne muscular dystrophy, including the investigational SGT-003 program and the POLARIS-101 capsid platform. These presentations underscore the company's commitment to developing innovative genetic medicines.

Read more →
SLDB
Oct 1, 2026
SLDBGeneral

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Inc. has announced the grant of 8,150 restricted stock units (RSUs) to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employee's continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent in the field of genetic medicine.

Read more →
SLDB
Sep 2, 2026
SLDBConferences/Events

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc. announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference and the Citi Biopharma Back to School Conference. Key executives will engage in fireside chats to discuss the company's advancements in precision genetic medicines targeting rare neuromuscular and cardiac diseases. Webcasts of these events will be available for investors.

Read more →
SLDB
Aug 6, 2026
SLDBPhases

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported its financial results for Q2 2026, highlighting progress in its clinical trials for SGT-003 and SGT-212. The company plans to meet with the FDA to discuss SGT-003's data and potential accelerated approval. Additionally, the Phase 3 IMPACT DUCHENNE trial has commenced, and initial data from the Friedreich's Ataxia trial is anticipated in early 2027. Despite a growing cash position, the company reported a net loss of $54.8 million for the quarter.

Read more →
SLDB
Jun 2, 2026
SLDBGeneral
▼ -8.5%on this news

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026

Solid Biosciences Inc. has announced the grant of 6,580 restricted stock units (RSUs) to a newly hired employee. This grant is part of the company's 2024 Inducement Stock Incentive Plan and is intended to incentivize the employee's acceptance of the job. The RSUs will vest over four years, contingent on the employee's continued service.

Read more →
SLDB
May 13, 2026
SLDBPhases

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported its Q1 2026 financial results, highlighting significant advancements in its clinical trials for Duchenne muscular dystrophy and Friedreich's ataxia. The company has initiated the Phase 3 IMPACT DUCHENNE trial and received positive regulatory feedback from the EMA. Additionally, Solid maintains a robust cash position, supporting its ongoing development efforts.

Read more →
SLDB
May 7, 2026
SLDBPhases

Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy

Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy

Read more →
SLDB
May 4, 2026
SLDBGeneral

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

Solid Biosciences Inc. has announced the grant of 8,070 restricted stock units to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. This grant, which vests over four years, is intended to incentivize the new employee's acceptance of the position. The company continues to advance its pipeline of gene therapies targeting rare neuromuscular and cardiac diseases.

Read more →
SLDB
May 1, 2026
SLDBGeneral

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4

Read more →
SLDB
Apr 30, 2026
SLDBConferences/Events

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences Inc. will present its largest scientific program at the 29th Annual Meeting of the ASGCT, featuring 16 presentations including 5 oral and 11 poster presentations. The event highlights the company's advancements in gene therapies for neuromuscular and cardiac diseases, showcasing their commitment to innovation and clinical development. CEO Bo Cumbo emphasized the significance of this meeting for Solid's growth and scientific rigor.

Read more →
SLDB
Apr 28, 2026
SLDBFDA Updates

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences has announced that the European Commission granted Orphan Drug Designation for SGT-003, aimed at treating Duchenne muscular dystrophy. This designation reflects the drug's potential to address significant unmet medical needs. SGT-003 is currently being evaluated in two clinical trials, INSPIRE DUCHENNE and IMPACT DUCHENNE, as part of a broader international development strategy.

Read more →
SLDB
Mar 19, 2026
SLDBGeneral

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Read more →
SLDB
Mar 11, 2026
SLDBPhases
▼ -5.7%on this news

Solid Biosciences Provides Interim Positive Clinical Update

Solid Biosciences has reported positive interim results from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy for Duchenne muscular dystrophy. Key findings include robust microdystrophin expression and improvements in muscle integrity and cardiac function among the 40 participants dosed. The company plans to engage with the FDA regarding a potential accelerated approval pathway for SGT-003.

Read more →
SLDB
Mar 9, 2026
SLDBConferences/Events
▲ +18.8%on this newsshared move

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Inc. will present its investigational gene therapies SGT-003 and SGT-212 at the 2026 MDA Clinical & Scientific Conference in Orlando. The presentations will cover the Phase 1/2 study of SGT-003 for Duchenne muscular dystrophy and the investigational gene therapy SGT-212 for Friedreich’s ataxia. The conference will take place from March 8-11, 2026.

Read more →

About Solid Biosciences Inc.

Charlestown, MA 121 employees solidbio.com
Headquarters500 RUTHERFORD AVENUE, CHARLESTOWN, MA, 02129
BIOPHARMAWATCH ELITE
Trade the next SLDB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime